
European Commission Announces Public Hearing on Phthalates in Medical Devices
Interested participants are required to register by the 17 March, 2024, with the event operating on a first-come, first-served basis due to limited space.

In a significant step towards addressing public health concerns, the European Union, through the European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), has opened a public consultation on the preliminary update of the SCHEER guidelines. This initiative focuses on the benefit-risk assessment of the presence of phthalates in certain medical devices, particularly those identified as carcinogenic, mutagenic, toxic to reproduction (CMR), or having endocrine-disrupting (ED) properties.
Status: OpenOpening Date: 21 March 2024Deadline: 28 April 2024, 23:59 (CEST)Target Audience: Public health community
This consultation is crucial for the advancement of safer medical devices and invites input from all relevant stakeholders, including manufacturers, notified bodies, regulatory entities, and the general public.
The updated guidelines serve a vital role in ensuring the safety and efficacy of medical devices that contain phthalates with CMR or ED properties. Key aspects of the guidelines include:
Evaluation of possible alternatives to phthalates used in medical devices.Methodology for performing a benefit-risk assessment to justify the presence of CMR/ED phthalates in medical devices.Support for assessments of other CMR/ED substances in medical devices.
The initiative underscores the EU's commitment to public health and safety by regulating the use of potentially harmful substances in medical devices. By revising the SCHEER guidelines, the European Commission aims to reflect the latest scientific evidence and promote the development and use of safer alternatives.
Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments through the designated electronic template by the specified deadline. This process allows for a comprehensive review of the scientific basis of the guidelines and identification of areas requiring further investigation.
SCHEER has reiterated the importance of manufacturers generating high-quality data on alternatives to CMR/ED phthalates in medical devices. Such data are crucial for informed decision-making and the development of safer medical products.
The feedback obtained from this consultation will play a pivotal role in shaping the final guidelines, ensuring they effectively address the risks associated with phthalates in medical devices. The European Commission's proactive approach, through SCHEER, highlights the ongoing efforts to enhance public health protections within the EU.
This public consultation represents a collaborative effort to refine regulatory standards and promote the safety of medical devices across Europe. Stakeholders are urged to participate actively in this critical consultation process.




Interested participants are required to register by the 17 March, 2024, with the event operating on a first-come, first-served basis due to limited space.

ECHA’s latest hazard classification consultation places silver chloride and several reproductive toxicants under scrutiny. With wide-ranging hazard classes proposed, the outcome could reshape compliance obligations, supply chains and risk management practices across multiple industries before the June 2026 deadline.

The EU REACH Committee will debate major restrictions on CMRs in childcare products and lead ammunition, while NGOs criticise delays in wider chemical regulation. The proposals could tighten compliance requirements across European supply chains.
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at